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SUMMARY
In a clinical trial of 25 Bantu and Indian patients over an
average period of 6 months, control of blood pressure was
obtained in 8 of the 12 Indian patients (66%) and in only 4
of the 13 Bantu patients (30%). This work shows that con-
trol of blood pressure in non-White patients on propranolol
is possible provided a large dose and prolonged period of
therapy are used; however, the control of blood pressure is
not as effective as in White patients.
Propranolol (Inderal), an adrenergic beta-receptor antaCfo-
nist, has been found to be an effective hypotensive ag~nt
in European patients.'" However, Humphreys and Delvin5
found in a double-blind cross-over trial of 18 hypertensive
Jamaicans that there was no significant difference between
propranolol and an inert placebo. To our knowledge,
there is no confirmatory work in the literature recording
the value of propranolol in the treatment of hypertension
among Bantu and Indian patients living in a tropical en-
vironment. With this in mind, a trial of propranolol among
Bantu and Indian patients living in this environment was
initiated.
MATERIAL AND METHOD
The trial started with 28 patients. Three patients were
withdrawn because of cardiac failure in one, insomnia in
another and a pulse rate below 50/inin in a third, leaving
25 patients who completed the trial at the end of 6 months.
Thirteen patients were Bantu, of whom 5 were males and
8 females. There were 12 Indians, comprising 7 males and
5 females. Two patients were in the age-group 20 - 30 years,
13 were aged 31 - 40 years, 6 were aged 41 - 50 years and
4 were 51 - 60 years.
Twelve patients had normal fundi, 10 patients had
vascular changes and 3 patients had either exudates or
haemorrhages seen in the fundi. Twenty-four patients had
essential hypertension and one patient had renal hyper-
tension. Before therapy 14 patients had electrocardiographic
or radiographic evidence of left ventricular hypertrophy.
An additional patient had had a posterior myocardial
infarction.
The blood urea level at the beginning of the trial was
as follows: below 40 mg/100 ml 21 patients; 40 - 50 mg/
100 ml 2 patients; 50 - 60 mg/100 ml 1 patient; and 60 - 90
mg/100 ml 1 patient.
The initial diastolic blood pressure in mmHg was 100-
"Date received: 7 December 1970.
120 in 5 cases; 121 - 140 in 14 cases and 141 - 160 in 6
cases.
Patients suffering from bronchial asthma or incipient or
overt manifestations of cardiac failure were excluded from
the trial.
Initially, the patients received propranolol 10 mg q.i.d.
and when this test dose was without effect, they were put
on propranolol 40 mg q.i.d. Thereafter, the dosage was
increased by 40 mg q.i.d. at fortnightly intervals until the
desired drop in blood pressure was reached and stopped
if the pulse rate dropped below 50/ minute, or if side-effects
which the patient could not tolerate developed. Of the 25
patients, 19 had attended the hypertension clinic regularly
and 6 were new cases. In the old patients blood pressure
had been successfully controlled by a variety of agents
including methyldopa, guanethidine, clonidine and reserpine
combined with a thiazide derivative. Two of the Indians
and 9 of the Bantu patients were of the professional class.
The aim of therapy was to lower the diastolic blood
pressure to a level of 110 mmHg or less and we regarded
patients as having mild control of their blood pressure if
their standing diastolic blood pressure was between 101
and 110 mmHg; moderate control if their standing diastolic
blood pressure was between 91 and 100 mmHg and good
control if their standing diastolic blood pressure was 90
mmHg or less. We define tolerance as a state in which an
increase in the dosage of propranolol becomes necessary
due to a rise in the blood pressure after a diastolic reading
of 110 mmHg has been attained.
RESULT OF THERAPY
Using the above criteria, we found that among the Indian
patients, 5 patients obtained good control, 2 patients ob-
tained moderate control and 1 mild control of their blood
pressure. Tolerance occurred in 3 Indian patients. In the
Bantu patients, 2 patients obtained good control of their
blood pressure, 1 patient obtained moderate control and
1 patient mild control of his blood pressure. Tolerance
occurred in 4 of the Bantu patients.
Table I shows the initial blood pressure, the response
to therapy on propranolol and the dosage of propranolol.
The dosage of propranolol in the 12 Indian patients varied
from 160 to 1920 mg daily with an average of 760 mg. The
dosage of propranolol in the 13 Bantu patients varied
from 320 mg daily to 1 600 mg daily with an average of
761 mg.
In 6 of the 25 patients the diastolic blood pressure did
not at any stage fall -to 110 mmHg or less. Fifteen of the
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25 patients in whom a diastolic level of 110 mmHg was
recorded, obtained this level within one month. Others
obtained the level between 2 and 4 months. It is relevant
that 19 patients were previously treated on other hypo-
tensive agents, and of two patients who were controlled
on guanethidine, one was not controlled on propranolol.
The others had been effectively treated on alpha-methyl-
dopa, clonidine or reserpine and a thiazide derivative.
In the 6 patients (5 Bantu) in whom no control was
obtained, the first was treated on propranolol 640 mg daily
for 6 months; the second received propranolol 1 600 mg
daily for 4 months; the third had propranolol 400 mg
daily for one month when marked bradycardia limited
TABLE I. INITIAL BLOOD PRESSURE, RESPONSE ON TIIERAPY TO
PROPRANOLOL ~~TI THE DOSAGE OF PROPRANOLOL
Standing
diastolie blood Maximum
Initial diastolie pressure dosage of
blood pressure mmHg on propranolol
Case Raee (mmHg) therapy (mg)
1 Indian 150 130 1280
2 Indian 120 90 160
3 Indian 130 100 480
4 Indian 150 90 1280
5 Indian 140 130 600
6 Indian 140 125 1920
7 Indian 140 130 1640
8 Indian 120 90 240
9 Indian 150 90 320
10 Indian 140 100 400
11 Indian 140 90 640
12 Indian 140 110 160
13 Bantu 130 90 320
14 Bantu 120 110 640
15 Bantu 120 90 400
16 Bantu 130 120 400
17 Bantu 130 120 1200
18 Bantu 140 130 400
19 Bantu 150 140 1600
20 Bantu 160 150 1480
21 Bantu 120 100 480
22 Bantu 130 120 400
23 Bantu 135 130 600
24 Bantu 130 120 800
25 Bantu 150 120 1200
further increase: the fourth was given propranolol! 920 mg
daily for 5 mo~ths; the fifth 1 600 mg daily for 2 mo.nths
and the sixth 1 920 mg daily for 6 months. Of the 6 patIents
who were resistant to propranolol 3 were new cases, 2 had
previously been controlled on alpha-methyldopa ~'5 g da~ly
and one on guanethidine 100 mg daily combllled With
cyclopenthiazide and reserpine.
The average gap between lying and standing blood
pressure was 5 mmHg.
Side-effects observed were insomnia, vomltmg, nausea,
bradycardia, sleepiness and diarrhoea (once each), an~ 14
patients had a weight gain of 2 kg. One patient complamed
that the number of tablets (20) was excessive. There was
no rise in the blood urea level in any patient.
DISCUSSION
This work sought to find out whether propranolol given
in high dosage and over a suffici~nt period of. time w?uld
lower the blood pressure in Bantu and Indian ~a~l~nts
living in a subtropical climate. Humphreys and Delvm III a
10
-
study of 18 Jamaicans with hypertension who were not of
completely negroid stock, concluded thal propranolol alone
up to a maximum of 360 mg given continuously for 2 - 4
months had no hypotensive effect. One of the main criti-
cisms of this work by Prichard and Gillam' was that the
dosage of propranolol was not high enough.
Humphreys and Delvin' also found that propranolol was
no more effective than an inert placebo and suggested that
this may have been because the 'tranquillizing' effect is
unlikely to be of value in Jamaicans. Zacharias and Cowen:
however, found in a randomized, double-blind cross-over
trial that propranolol produced a significant fall in blood
pressure when compared with a placebo in 28 European
patients with hypertension.
This study showed that when a high dosage of pro-
pranolol is used, control of blood pressure can be attained.
Only 4 Indians and one Bantu were controlled with the
maximum dose suggested by Humphreys and Delvin, viz.
360 mg daily. Among our 12 Indian patients, 5 obtained
good control, 2 moderate control and I patient mild
control of blood pressure. In the 13 Bantu, 2 obtained
good control, one moderate control and one mild control.
Thus there was a racial difference in the response to pl'o-
pranolol, used for hypertension, in that Bantu patients did
not respond as effectively as Indians.
The advantage of propranolol, as noted by Prichard and
Gillam,' was that the average gap between lying and
standing blood pressure was only 5 mmHg. The other
advantage was that side-effects occurred in only 6 of the
25 patients but except for one patient with bradycardia
the side-effects were not serious enough to warrant dis-
continuing propranolol. It is important carefully to ex-
clude those suffering from cardiac failure or bronchial
asthma, as one patient in our series developed congestive
cardiac failure.
We have found that propranolol, while it is an effective
drug in the control of blood pressure in high dosage, is
not as effective a hypotensive agent as guanethidine or
methyldopa. This work is in contrast to that of Prichard
and Gillam' who found that propranolol is at least of
similar potency to bethanidine, guanethidine and methyl-
dopa. Two patients who were previously controlled on
methyldopa and one patient previously controlled on
guanethidine, reserpine and a thiazide derivative were in-
effectively controlled on propranolol. The disadvantage of
using propranolol in hypertension is its property of exacer-
bating congestive cardiac failure or bronchial asthma. The
average dosage of propranolol used in our series was 760
m o daily in Bantu and 761 mg in the Indian patients.
With such doses the retail cost of the drug would prohibit
its liberal use, especially in a tropical or subtropical en-
vironment where the cost of therapy is an important factor.
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